Gregg Stone
Cardiovascular Disease · New York, NYNPI 1134206956
Payments from drug & device makers
Across 321 payments — averaging $11,540 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spectrawave, Inc$1.5M
- Heartflow, Inc.$430K
- Neovasc Medical Inc$256K
- Ancora Heart, Inc.$244K
- Elucid Bioimaging Inc$224K
- Abbott$208K
- plus $872K from 20 others
Across 30 payments — averaging $14,753 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Circulation Inc$443K
- Abiomed$84
What the payments were for
- Consulting fees$1,798,98890%
- Speaking & faculty fees$77,5634%
- Grants$28,8751%
- Travel & lodging$79,2994%
- Food & beverage$7,1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Spectrawave, Inc | 14 | $1,471,768 |
| Heartflow, Inc. | 30 | $429,991 |
| Neovasc Medical Inc | 53 | $255,745 |
| Ancora Heart, Inc. | 17 | $243,513 |
| Elucid Bioimaging Inc | 8 | $223,999 |
| Abbott | 54 | $207,799 |
| Impulse Dynamics (USA) Inc. | 15 | $187,783 |
| Shockwave Medical, Inc | 20 | $180,000 |
| Ablative Solutions, Inc. | 11 | $168,040 |
| Cardiovascular Systems Inc. | 11 | $157,343 |
| W. L. Gore & Associates, Inc. | 5 | $57,000 |
| Abiomed | 44 | $52,036 |
| Occlutech US LLC | 1 | $28,875 |
| Medtronic(2 entities) | 8 | $12,581 |
| Amgen | 3 | $10,710 |
| Genentech, Inc. | 2 | $3,029 |
| Lantheus Medical Imaging, Inc. | 1 | $3,000 |
| Daiichi Sankyo Inc. | 2 | $2,860 |
| Boehringer Ingelheim International GmbH | 1 | $2,400 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $2,000 |
| Cook Incorporated | 1 | $1,500 |
| Philips North America LLC | 13 | $1,203 |
| ZOLL Circulation Inc | 3 | $1,023 |
| Penumbra, Inc. | 1 | $235 |
| United Therapeutics Corporation | 1 | $33 |
| Boston Scientific | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$354,322
- FFRct$297,168
- PlaqueIQ$121,499
- AccuCinch$108,371
- ElucidVivo$102,500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$90,000
- MitraClip$61,281
- Product in Development$57,000
- Impella$51,871
- Vascular Lithotripsy$45,000
- Repatha$10,710
- OPTIMIZER SMART SYSTEM$10,414
- RESOLUTE ONYX$9,350
- Absorb GT1$8,786
- Architect$6,638
- XIENCE SIERRA$6,299
- OPTIS$6,245
- Ultreon$3,901
- Definity$3,000
- TNKase$2,950
How this compares
$3,704,491 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
- Cezar StaniloaeNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.